Treatment combo nearly doubles survival time in lung cancer patients, study finds

Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compa...

Posted: Apr 16, 2018 2:00 PM
Updated: Apr 16, 2018 2:00 PM

Combining an immunotherapy drug with chemotherapy nearly doubled the survival time of some lung cancer patients compared to patients treated with chemotherapy alone, new research published Monday in the New England Journal of Medicine showed.

The study results apply only to patients whose lung cancer does not begin in the squamous cells (or surface lung cell layer) and who also lack certain genetic mutations. Of the two types of lung cancer, small cell lung cancer is less common than non-small cell lung cancer, which affects up to 85% of all lung cancer patients. Worldwide, lung cancer causes 1.69 million deaths annually.

Non-small cell lung cancer is the leading cause of cancer death in the world

Immunotherapy plus chemotherapy nearly doubled survival of patients with advanced disease

"Non-small cell lung cancer is actually the leading cause of cancer death in the world even though it's not the most common cancer," said Dr. Leena Gandhi, lead investigator of the study and director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health.

Gandhi explained that the reason non-small cell lung cancer is so deadly is the existing chemotherapy drugs provide only limited survival benefits for patients. "A matter of months, not years," she said.

Immunotherapy, which harnesses the body's immune system to attack tumors, is known to improve survival in patients who have already been treated with chemo.

Gandhi wondered, Would using immunotherapy earlier in treatment, alongside chemotherapy, do more for patients?

The study, a phase III clinical trial testing treatment effectiveness and side effects, included 616 patients at 118 medical facilities around the globe.

One group of 400 patients received standard chemotherapy and the immunotherapy drug pembrolizumab, while a smaller group of patients received chemotherapy.

Pembrolizumab, sold under the brand name Keytruda, is an FDA-approved drug sold by a subsidiary of Merck & Company, Inc. that sponsored this study.

The combined use of standard chemotherapy with pembrolizumab was "superior in terms of response -- keeping people alive without progression of their cancer -- and improving the overall survival of patients with metastatic lung cancer compared to chemotherapy alone," said Gandhi. "And the differences were not small."

For patients receiving the combined therapy, the chance of death or progression of their cancer was reduced by 48% compared to the patients receiving only chemotherapy. The most common side effects were nausea, anemia and fatigue and in both groups about 65% of patients experienced severe side effects. However, the risk of one side effect, acute kidney injury, was higher for combination treated patients: 5.2% vs. 0.5%.

Dr. Jorge Gomez, a volunteer spokesperson for the American Lung Association and a medical oncologist and director of thoracic oncology at Mount Sinai Hospital in New York, explained that "about 220,000 patients are diagnosed with lung cancer a year in the US."

Non-squamous lung cancer patients make up about 80% of all the non-small cell lung cancers, so that amounts to over 150,000 patients in the US each year, said Gomez, who was not involved in the new study.

"What we look at in these trials is overall survival -- how long patients live -- and we look at a number called the median survival -- how long 50% of patients live," said Gomez. Median survival is met when 50% of the patients die.

For non-squamous non-small cell lung cancer patients, median survival with chemotherapy alone is somewhere around 11 or 12 months, he said. Yet, median survival among the study participants who received both immunotherapy and chemo has not yet been reached.

"It's already been 21 months," said Gomez. "The differences are big enough now that you know it's going to be a very big number and it's important to get this information to people so they can start using this regimen."

Gomez believes it could be as high as double chemotherapy alone, "which would be very impressive," he said. "I only treat lung cancer and I've been doing that for about 20 years. These drugs are very, very interesting. Now, not everybody benefits unfortunately, but some of the people who benefit seem to benefit in a way we've never seen."

Recalling a patient with advanced lung cancer whose tumor disappeared and has not grown back after finishing treatment 24 months ago, Gomez said, "I'm now becoming much more optimistic that if we can really find a way to perfect this treatment and to really figure out who are the patients who do the best and why that we may be able to do something like get rid of lung cancer for at least some patients."

Huntsville/Redstone
Partly Cloudy
52° wxIcon
Hi: 52° Lo: 31°
Feels Like: 52°
Muscle Shoals
Clear
56° wxIcon
Hi: 56° Lo: 30°
Feels Like: 56°
Huntsville/Madison
Partly Cloudy
52° wxIcon
Hi: 53° Lo: 29°
Feels Like: 52°
Decatur
Partly Cloudy
52° wxIcon
Hi: 55° Lo: 31°
Feels Like: 52°
Fort Payne
Partly Cloudy
50° wxIcon
Hi: 52° Lo: 33°
Feels Like: 50°
WAAY Radar
WAAY WAAY-TV Cam
WAAY Temperatures

Alabama Coronavirus Cases

Cases: 422598

Reported Deaths: 6120
CountyCasesDeaths
Jefferson62039921
Mobile30225548
Madison27052186
Tuscaloosa20728267
Montgomery18978305
Shelby18504114
Baldwin16251182
Lee12465101
Morgan12233113
Etowah11735168
Calhoun11122200
Marshall10191107
Houston8598148
Cullman8023105
Limestone800274
Elmore7836101
DeKalb768397
Lauderdale754683
St. Clair7535120
Talladega6166108
Walker5897174
Jackson580341
Colbert532073
Blount530483
Autauga518455
Coffee441056
Dale396181
Franklin366248
Chilton336165
Russell330310
Covington327268
Escambia316842
Dallas303196
Chambers282769
Clarke281433
Tallapoosa2616107
Pike248729
Marion245650
Lawrence243647
Winston226635
Bibb215147
Geneva201435
Marengo199029
Pickens196531
Hale175842
Barbour172936
Butler169658
Fayette168226
Cherokee160330
Henry153621
Monroe145217
Randolph139835
Washington137626
Clay126145
Crenshaw118744
Lamar118019
Cleburne117423
Macon114735
Lowndes110335
Wilcox103121
Bullock99028
Perry97419
Conecuh94420
Sumter89026
Greene76023
Coosa60515
Choctaw51224
Out of AL00
Unassigned00

Tennessee Coronavirus Cases

Cases: 685321

Reported Deaths: 8391
CountyCasesDeaths
Shelby761671128
Davidson70706661
Knox38646393
Hamilton34556326
Rutherford33114283
Unassigned22759126
Williamson21364138
Sumner18205230
Out of TN1612079
Wilson14405155
Montgomery14367149
Sullivan12577211
Washington11889191
Blount11887124
Maury10941123
Bradley1075190
Sevier10461108
Putnam9931136
Madison9099178
Robertson761885
Hamblen6954109
Anderson6759102
Greene6569108
Tipton619065
Gibson5630111
Coffee560681
Cumberland537872
Dickson534678
Bedford532086
Roane519179
Carter5091112
Lawrence507569
McMinn506673
Warren497553
Loudon493750
Jefferson474975
Dyer473682
Monroe455162
Hawkins444968
Franklin410758
Obion399478
Fayette396251
Rhea381556
Lincoln378344
Marshall343536
Cocke342856
Weakley339448
Cheatham335230
Henderson332056
Campbell323940
Giles321071
White310043
Hardeman308752
Carroll307859
Hardin297647
Lauderdale293131
Macon287350
Wayne260719
Henry260358
Overton252942
DeKalb241741
Haywood239745
McNairy238142
Smith230527
Trousdale228714
Marion227731
Scott225231
Hickman222734
Fentress212531
Claiborne210129
Grainger208135
Johnson201532
Morgan188614
Crockett180338
Bledsoe174110
Chester173237
Unicoi166843
Cannon157019
Lake155319
Decatur147226
Polk142817
Grundy139320
Union138721
Sequatchie136518
Humphreys132617
Benton131935
Lewis127220
Meigs114016
Stewart105220
Jackson103721
Perry94725
Houston93922
Clay93726
Moore7959
Pickett67619
Van Buren6587
Hancock4026

Community Events